Development of a high-throughput screening assay for inhibitors of aggrecan cleavage using luminescent oxygen channeling (AlphaScreen™)

被引:34
作者
Peppard, J [1 ]
Glickman, F [1 ]
He, Y [1 ]
Hu, SI [1 ]
Doughty, J [1 ]
Goldberg, R [1 ]
机构
[1] Novartis Inst Biomed Res, Summit, NJ USA
关键词
aggrecan; AlphaScreen; MMP; high-throughput screening;
D O I
10.1177/1087057103252308
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Aggrecan is one of the most important structural components of joint cartilage, and members of the metalloprotease (MMP) and ADAM (a disintegrin and metalloproteinase) protease families have been shown to degrade aggrecan in vivo. A robust assay for aggrecan-degrading activity suitable for high-throughput screening (HTS) was set up and measured using AlphaScreen(TM). In this technology, beads brought into proximity through cross-linking and stimulated with laser light generate a signal through luminescent oxygen tunneling, the outcome of which is a time-resolved fluorescent signal. Specific antibodies to the carbohydrate side chains of aggrecan were harnessed to create a scaffold whereby aggrecan could form a cross-link between donor and acceptor AlphaScreen detector beads. Digested aggrecan, which failed to form a cross-link, generated no signal, so that inhibitors of the digestion could be detected as a restoration of signal. The development of this assay and its validation for HTS are described in this report.
引用
收藏
页码:149 / 156
页数:8
相关论文
共 21 条
[1]   Aggrecanase - A target for the design of inhibitors of cartilage degradation [J].
Arner, EC ;
Pratta, MA ;
Decicco, CP ;
Xue, CB ;
Newton, RC ;
Trzaskos, JM ;
Magolda, RL ;
Tortorella, MD .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :92-107
[2]  
BARTNIK E, 1999, Patent No. 5872209
[3]   Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors [J].
Bottomley, KM ;
Borkakoti, N ;
Bradshaw, D ;
Brown, PA ;
Broadhurst, MJ ;
Budd, JM ;
Elliott, L ;
Eyers, P ;
Hallam, TJ ;
Handa, BK ;
Hill, CH ;
James, M ;
Lahm, HW ;
Lawton, G ;
Merritt, JE ;
Nixon, JS ;
Rothlisberger, U ;
Whittle, A ;
Johnson, WH .
BIOCHEMICAL JOURNAL, 1997, 323 :483-488
[4]   INHIBITION OF CARTILAGE PROTEOGLYCAN RELEASE BY A SPECIFIC INACTIVATOR OF CATHEPSIN-B AND AN INHIBITOR OF MATRIX METALLOPROTEINASES - EVIDENCE FOR 2 CONVERGING PATHWAYS OF CHONDROCYTE-MEDIATED PROTEOGLYCAN DEGRADATION [J].
BUTTLE, DJ ;
HANDLEY, CJ ;
ILIC, MZ ;
SAKLATVALA, J ;
MURATA, M ;
BARRETT, AJ .
ARTHRITIS AND RHEUMATISM, 1993, 36 (12) :1709-1717
[5]   Mechanisms involved in cartilage proteoglycan catabolism [J].
Caterson, B ;
Flannery, CR ;
Hughes, GE ;
Little, CB .
MATRIX BIOLOGY, 2000, 19 (04) :333-344
[6]   INTERLEUKIN-1 AND ONCOSTATIN-M IN COMBINATION PROMOTE THE RELEASE OF COLLAGEN FRAGMENTS FROM BOVINE NASAL CARTILAGE IN CULTURE [J].
CAWSTON, TE ;
ELLIS, AJ ;
HUMM, G ;
LEAN, E ;
WARD, D ;
CURRY, V .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 215 (01) :377-385
[7]   A STROMELYSIN ASSAY FOR THE ASSESSMENT OF METALLOPROTEASE INHIBITORS ON HUMAN AGGREGATED PROTEOGLYCAN [J].
DOUGHTY, JR ;
GOLDBERG, RL ;
GANU, V ;
MELTON, RA ;
HU, SI ;
DIPASQUALE, G .
AGENTS AND ACTIONS, 1993, 39 :C151-C153
[8]   DEVELOPMENT OF A CLEAVAGE-SITE-SPECIFIC MONOCLONAL-ANTIBODY FOR DETECTING METALLOPROTEINASE-DERIVED AGGRECAN FRAGMENTS - DETECTION OF FRAGMENTS IN HUMAN SYNOVIAL-FLUIDS [J].
FOSANG, AJ ;
LAST, K ;
GARDINER, P ;
JACKSON, DC ;
BROWN, L .
BIOCHEMICAL JOURNAL, 1995, 310 :337-343
[9]   Aggrecan is degraded by matrix metalloproteinases in human arthritis - Evidence that matrix metalloproteinase and aggrecanase activities can be independent [J].
Fosang, AJ ;
Last, K ;
Maciewicz, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) :2292-2299
[10]   Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site.: Efficient aggrecanase catabolism may depend on multiple substrate interactions [J].
Hörber, C ;
Büttner, FH ;
Kern, C ;
Schmiedeknecht, G ;
Bartnik, E .
MATRIX BIOLOGY, 2000, 19 (06) :533-543